American medical device company St Jude Medical revealed that it has received the CE Mark approval for its next generation portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), Ellipse and SJM Assura.
Both the devices will feature the DynamicTx Over-Current Detection Algorithm which will ensure the delivery of high-voltage therapy, in case of an electrical short in one portion of the system, by automatically adjusting shocking configurations within the device.
AdvertisementThey will also come with low friction coating on the device can that reduces the friction between the device and leads.
"The goal for this innovative portfolio of devices is to bring implantable defibrillation reliability and patient safety to the next level. The new Ellipse ICD and Assura family of devices demonstrates St. Jude Medical's commitment to developing technologies that provide physicians with advanced patient management tools to mitigate the most common ICD lead complications, especially those that can lead to ineffective high voltage therapy delivery", the president of the St. Jude Medical Implantable Electronic Systems Division, Eric S. Fain said.